Hologic, Inc.

HOLX

NASDAQ · Diagnostics & Lab Testing

$76.01

At close - USD

Market Cap$16.97B

P/E30.5x

52W High$76.07

Volume101.96M

VCP Research Verdict2026Q1

Stagnant Revenue Growth Masks Underlying Margin Volatility

Hologic faces a challenging post-pandemic transition characterized by muted 2.5% year-over-year revenue growth in 2026Q1 and significant earnings volatility.

GrowthMixed

ProfitabilityModerate

ValuationAttractive

TechnicalsStrong

Explore valuation models

MARKET ACTION

HOLX price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis

Fundamental Trajectory

Revenue growth remains constrained at 2.5% in 2026Q1, while gross margins have fluctuated significantly from a low of 37.5% in 2025Q2 to 56.0% in the most recent quarter.

Analyst Consensus+3.5% target

Hold(42 analysts)

18 Buy23 Hold1 Sell

The Bull Case

Upside Catalysts

Women's health focus

Hologic specializes in diagnostics, surgical, and medical imaging technologies dedicated to advancing women's health, a growing and underserved market.

Regulatory approvals secured

The company has received all necessary regulatory approvals for its $18.3 billion sale to private equity firms, signaling strong investor confidence.

Attractive valuation

With a current stock price around $65.16, Hologic may present a buying opportunity for growth investors in the healthcare equipment sector.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

HOLX+1.94%

S&P 500 (^GSPC)+7.63%

1-Year Return

HOLX+2.51%

S&P 500 (^GSPC)+9.69%

3-Year Return

HOLX+10.48%

S&P 500 (^GSPC)+68.76%

5-Year Return

HOLX+6.86%

S&P 500 (^GSPC)+56.80%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E

N/A

Forward P/E

17.2x

EV/EBITDA

N/A

FCF YieldCash Flow

N/A

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

N/A

24.5x

N/A

EV/EBITDA

N/A

15.7x

N/A

Price/FCF

N/A

16.6x

N/A

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

Bear$51.63-32.1%

Base (Fair)$87.49N/A

Bull$144.04+89.5%

$51.63 Bear$87.49 Base$144.04 Bull

Current Market Price: $76.01

Trades at a 13.1% discount to Base DCF ($87.49)

Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend

Revenue FY25

$4.1B+1.7% YoY

Net income FY25

$566M-28.3% YoY

Free cash flow FY25

$920M-19.6% YoY

Operating margin FY25

17.4%-4.5 pts YoY

ROIC (FY25)9.4%

Avg ROIC 5Y-

ROE (FY25)11.1%

Piotroski Score7 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate10/12 (83%)

Revenue Beat Rate10/12 (83%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest Jan 29, 2026	$1.04-4.6% vs $1.09	$1.0B-2.2% vs $1.1B
Q4 2025 Nov 3, 2025	$1.13+2.7% vs $1.10	$1.0B+1.5% vs $1.0B
Q3 2025 Jul 30, 2025	$1.08+2.9% vs $1.05	$1.0B+1.3% vs $1.0B
Q2 2025 May 1, 2025	$1.03+1.0% vs $1.02	$1.0B+0.5% vs $1.0B

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

1 Story

Business Wire·Oct 19, 2026

Hologic Signs Definitive Agreement to Acquire Reveal Genomics

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, a global leader in women's health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Revea.

Filtered for Hologic, Inc.More Headlines

Compare before deciding

Benchmark HOLX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Hologic, Inc. (HOLX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
HOLXHologic, Inc.Current	$76.01	$16.97B	30.53	1.74%	13.8%	11.12%	—
BDXBecton, Dickinson and Company	$211.88	$58.38B	36.34	8.23%	4.52%	3.79%	1.97%
BAXBaxter International Inc.	$25.79	$13.32B	-14.74	5.72%	-6.23%	-11.67%	2.63%
IDXXIDEXX Laboratories, Inc.	$676.04	$53.33B	51.69	10.42%	25.36%	71.18%	—
DXCMDexCom, Inc.	$79.41	$30.64B	38.00	15.6%	19.41%	36.5%	—
ISRGIntuitive Surgical, Inc.	$452.80	$159.96B	57.53	20.51%	25.54%	16.91%	—

Compare HOLX vs Peers

Hologic, Inc. (HOLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BDX

Most directly comparable listed peer for HOLX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare HOLX against a more recognizable public peer.

Peer Set

Compare Top 5

vs BDX, BAX, IDXX, DXCM

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

HOLX SEC Filings & Documents

Hologic, Inc. (HOLX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 7, 2026·SEC

Material company update

Apr 6, 2026·SEC

Material company update

Feb 6, 2026·SEC

10-K Annual Reports

FY 2025

Nov 18, 2025·SEC

FY 2024

Nov 27, 2024·SEC

10-Q Quarterly Reports

FY 2026

Jan 29, 2026·SEC

FY 2025

Jul 31, 2025·SEC

FY 2025

May 2, 2025·SEC

Get notified when HOLX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

HOLX Frequently Asked Questions

Hologic, Inc. (HOLX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Hologic, Inc.'s revenue?

Hologic, Inc. (HOLX) reported $4.13B in revenue over the trailing twelve months. Revenue was $4.10B in fiscal year 2025. That is 4549% more than the $88.2M of fiscal year 1996.

How fast is Hologic, Inc. growing?

Hologic, Inc. (HOLX) grew revenue by 1.7% in fiscal year 2025, compared with the prior fiscal year.

Is HOLX profitable?

Yes. Hologic, Inc. (HOLX) earned $543.9M in net income over the trailing twelve months (a 13.2% net margin).

Dividend & Returns

What is HOLX's return on equity?

Hologic, Inc. (HOLX) had a return on equity (ROE) of 11.1% in fiscal year 2025. That is in line with the market's typical 10-15%.

What is Hologic, Inc.'s free cash flow?

Hologic, Inc. (HOLX) generated $999.6M in free cash flow over the trailing twelve months.

What if you invested $1,000 in HOLX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q1 2026Latest

Jan 29, 2026

$1.04-4.6%

vs $1.09

$1.0B-2.2%

vs $1.1B

Q4 2025

Nov 3, 2025

$1.13+2.7%

vs $1.10

$1.0B+1.5%

vs $1.0B

Q3 2025

Jul 30, 2025

$1.08+2.9%

vs $1.05

$1.0B+1.3%

vs $1.0B

Q2 2025

May 1, 2025

$1.03+1.0%

vs $1.02

$1.0B+0.5%

vs $1.0B

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

HOLXHologic, Inc.Current

$76.01

$16.97B

30.53

1.74%

13.8%

11.12%

—

BDXBecton, Dickinson and Company

$211.88

$58.38B

36.34

8.23%

4.52%

3.79%

1.97%

BAXBaxter International Inc.

$25.79

$13.32B

-14.74

5.72%

-6.23%

-11.67%

2.63%

IDXXIDEXX Laboratories, Inc.

$676.04

$53.33B

51.69

10.42%

25.36%

71.18%

—

DXCMDexCom, Inc.

$79.41

$30.64B

38.00

15.6%

19.41%

36.5%

—

ISRGIntuitive Surgical, Inc.

$452.80

$159.96B

57.53

20.51%

25.54%

16.91%

—